Browsing Tag
BlossomHill Therapeutics
1 post
Fast Track win puts BlossomHill’s BH-30643’s 50% early response signal gets FDA Fast Track backing as BlossomHill goes public
BH-30643 wins FDA Fast Track status as BlossomHill directs $70m of its fresh IPO capital toward its EGFR-resistant lung cancer program.